Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.77 |
| ▸ | CA2 | P00918 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | KDM1A | O60341 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4618930 | 0.88 | CA1 (0.62) | CA1CA2ALDH1A1MEN1KMT2A | |
| SCHEMBL6801249 | 0.87 | ALDH1A1 (0.77) | CA1CA2ALDH1A1MEN1KMT2A | |
| SCHEMBL9328712 | 0.87 | CA1 (0.75) | CA1CA2ALDH1A1MEN1KMT2A | |
| SCHEMBL28648021 | 0.86 | ALDH1A1 (0.66) | CA1CA2ALDH1A1MEN1KMT2A | |
| SCHEMBL4661775 | 0.85 | CA2 (0.76) | CA1CA2ALDH1A1MEN1KMT2A | |
| SCHEMBL10463532 | 0.85 | CA1 (0.71) | CA1CA2ALDH1A1MEN1KMT2A | |
| SCHEMBL6808050 | 0.84 | CA1 (0.63) | CA1CA2ALDH1A1MEN1KMT2A | |
| SCHEMBL10523653 | 0.83 | ALDH1A1 (0.79) | CA1CA2ALDH1A1MEN1KMT2A | |
| SCHEMBL6808541 | 0.83 | ALDH1A1 (0.79) | CA1CA2ALDH1A1MEN1KMT2A | |
| SCHEMBL4617786 | 0.83 | SFRP1 (0.79) | CA1CA2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004074238-A1 | PHENETHYLAMINO SULFAMIC ACIDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040167183-A1 | Phenethylamino sulfamic acids | THE PROCTER & GAMBLE COMPANY | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167183-A1 | Phenethylamino sulfamic acids | PTPRM, PTPRS, PTPRE | CA1 2299/4885CA2 1472/4885ALDH1A1 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.